Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinibDaniel W. Sherbenou, Michael W. Deininger, Patina M. Harrell et al.|Leukemia|2007Cited by 77
In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.Daniel W. Sherbenou, Michael W. Deininger, Matthew J. Wong et al.|Blood|2005Cited by 6